Inhibitory effect of the interferon-beta on the release of endothelial cell derived microparticles in patients with multiple sclerosis

Authors
Akbar Hashemi Tayer
Maryam Jalali
Maryam Kamravan
Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran
10.22034/pjms.2022.700533
Abstract
Introduction: Increased levels of microparticles (MPs) have been reported in many autoimmune diseases such as multiple sclerosis (MS). In MS, endothelial cells release MPs from their membranes following the activation of lymphocytes and the production of inflammatory cytokines. The aim of this study was to investigate the inhibitory effect of interferon beta (INFβ) on the release of endothelial cell-derived MPs (EnMPs).
Material and Methods: Twenty newly diagnosed MS patients were included in this study. Blood samples were taken from
patients in two stages before and three months after INFβ treatment. Flow cytometry was used to count and determine the phenotype of MPs. Anti-CD51 and anti-CD31 were used to tag EnMPs. In both stages, patients' MRI was also evaluated for the number of brain plaques. Data were analyzed using SPSS-23 statistical software.
Result: The mean age of patients was 31.3 ± 8.3 years. The results of this study showed a 40% decrease in the level of CD31+ MPs and a 32% decrease in the level of CD51+ MPs following treatment with INFβ, which was statistically significant (p <0.001). In this study, there was no positive and significant relationship between the number of EnMPs and the number of brain plaques (p = 0.067), age (p = 0.058) and sex of patients (p = 0.061).
Conclusion: INFβ has an inhibitory effect on the release of EnMPs from endothelial cells and suggest that EnMPs can probably be used as sensitive biomarkers to monitor disease progression and treatment effectiveness.

Keywords
Multiple Sclerosis
Interferon Beta
Endothelial Cell-Derived Microparticles
1- McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325(8):765–779. 2- Lublin FD, Reingold SC; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. "Defining the clinical course of multiple sclerosis: results of an international survey". Neurology 1996. 46 (4): 907–11 3- Nakahara J. Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy". Clinical reviews in allergy & immunology 2012; 42 (1): 26–34. 4- McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA 2021;325(8):765–79. 5- Zuroff LR, Benjamins JA, Bar-Or A, Lisak RP. Inflammatory mechanisms underlying cortical injury in progressive multiple sclerosis. Neuroimmunol Neuroinflammation 2021;8:111-33. 6- Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler. 2003 Dec;9(6):540-49. 7- Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000;101(8):841-43. 8- Amabile N, Guerin AP, Tedgui A, Boulanger CM, London GM. Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. Nephrol Dial Transplant 2012; 27 (5): 1873-80. 9- Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011; 31 (1): 27-33. 10- Minagar, A., W. Jy, J. J. Jimenez, W. A. Sheremata, L. M. Mauro, W. W. Mao, L. L. Horstman and Y. S. Ahn. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001; 56, 1319-1324. 11- Combes, V., A. C. Simon, G. E. Grau, D. Arnoux, L. Camoin, F. Sabatier, M. Mutin, M. Sanmarco, J. Sampol and F. Dignat-George. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest1999; 104, 93-102. 12- Jimenez JJ, Jy W, Mauro LM, Horstman LL, et al. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 2003; 123(5): 896-902. 13- Hai-xia Liao, Lin-lin Meng, Xin Yu, Ming Song, Guo-kai Shang, Di Wang, et al. Increased circulating erythrocyte-derived microparticles in patients with acute coronary syndromes. Biomarkers in Medicine 2021;15(10):741-51. 14- Preston, R. A., W. Jy and J. J. Jimeznez: Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003; 41, 211-217. 15- Gkaliagkousi E, Nikolaidou B, Gavriilaki E, et al. Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus. Diabetes and Vascular Disease Research 2019:458-465. 16- Hashemi Tayer A, Amirizadeh N, Ahmadinejad M, Nikougoftar M, Deyhim MR, Zolfaghari S. Procoagulant Activity of Red Blood Cell-Derived Microvesicles during Red Cell Storage. Transfusion Medicine and Hemotherapy 2019;46(4):224-30. 17- Marcos-Ramiro B, Nacarino PO, Serrano-Pertierra E, Blanco-Gelaz MÁ, Weksler BB, Romero IA, et al. Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function. BMC Neurosci 2014;15(1):110. 18- Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circulation research 2010;107(9):1047-57. 19- Sáenz-Cuesta M, Osorio-Querejeta I, Otaegui D. Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us? Front Cell Neurosci. 2014;8:100. 20- Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thrombosis research. 2003;109(4):175-80. 21- Jin T, Gu J, Li Z, Xu Z, Gui Y. Recent Advances on Extracellular Vesicles in Central Nervous System Diseases. Clin Interv Aging. 2021;16:257-74 . 22- Harris VK, Sadiq SA. Biomarkers of therapeutic response in multiple sclerosis: current status. Mol Diagn Ther. 2014;18(6):605-17. 23- Lowery-Nordberg M, Eaton E, Gonzalez-Toledo E, Harris MK, Chalamidas K, McGee-Brown J, et al. The effects of high dose interferon-β1a on plasma microparticles: correlation with MRI parameters. Journal of Neuroinflammation. 2011;8(1):1-6. 24- Jimenez JJ, Jy W, Mauro LM, Horstman LL, Ahn ER, Ahn YS, et al. Elevated endothelial microparticle—monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-β1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Multiple Sclerosis Journal. 2005;11(3):310-15. 25- Sheremata WA, Jy W, Delgado S, Minagar A, McLarty J, Ahn Y. Interferon-β1a reduces plasma CD31+ endothelial microparticles (CD31+ EMP) in multiple sclerosis. Journal of neuroinflammation. 2006;3(1):23. 26- Larkin M. Raised endothelial microparticles an early marker for multiple sclerosis? The Lancet. 2001;357(9269):1679.